NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

February 28, 2020

Tracey Liebman, MD, discusses the use of digital surveillance in melanoma.

February 28, 2020

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

February 19, 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

February 18, 2020

Julia Fehniger, MD, discusses emerging strategies in the treatment paradigm for patients with BRCA1/2-mutant endometrial cancer.

February 14, 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses the nuances of immunotherapy related adverse events in melanoma.

February 13, 2020

Diane M. Simeone, MD, discusses the impact of PARP inhibitors on pancreatic cancer.

February 12, 2020

In our exclusive interview, Jeffrey S. Weber, MD, PhD, shares with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.

January 31, 2020

Tracey Liebman, MD, discusses the toxicities associated with BRAF inhibitors in melanoma.

January 30, 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

January 28, 2020

Richard L. Shapiro, MD, discusses the evolution and current role of surgery in advanced melanoma.

January 27, 2020

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

January 27, 2020

Jeffrey S. Weber, MD, PhD, discusses adjuvant approaches in stage III melanoma.

January 27, 2020

Anna C. Pavlick, DO, discusses the importance of immunotherapy for patients with metastatic melanoma.

January 27, 2020

Catherine M. Diefenbach, MD, discusses polatuzumab vedotin (Polivy) plus obinutuzumab (Gazyva) and lenalidomide (Revlimid) in patients with follicular lymphoma.

January 24, 2020

Tracey Liebman, MD, discusses the identification and management of treatment-related dermatologic AEs in patients with melanoma.

January 22, 2020

Francisco J. Esteva, MD, PhD, discusses the cost-saving potential of biosimilars in breast cancer and historical experience with their use.

January 17, 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses optimal management of adverse events associated with various therapies for patients with melanoma.

January 16, 2020

Anna C. Pavlick, DO, discusses key trials that have shed light on how to best treat patients with newly diagnosed, metastatic melanoma.

January 16, 2020

David Polsky, MD, PhD, discusses the development and clinical utility of biomarkers in melanoma.

January 16, 2020

Jeffrey S. Weber, MD, PhD, discusses the activity of targeted therapy in metastatic melanoma, its adoption into the adjuvant setting, and the optimal use of immunotherapy in the space.